Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers
A Perez, T Al Sagheer, GR Nahas… - Frontiers in …, 2024 - frontiersin.org
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape
for hematological malignancies, showing high efficacy in patients with relapsed or refractory …
for hematological malignancies, showing high efficacy in patients with relapsed or refractory …
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia
KV Pal, M Othus, Z Ali, K Russell, C Shaw… - Blood …, 2024 - ashpublications.org
Febrile neutropenia (FN) is the most common reason for hospital readmission after
chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care …
chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care …